Rationale for DPP-4 Inhibitors as Bridge or Dose-Sparing Therapy in Patients Using GLP-1 Receptor Agonists or Tirzepatide: A Conceptual Framework

Rationale for DPP-4 Inhibitors as Bridge or Dose-Sparing Therapy in Patients Using GLP-1 Receptor Agonists or Tirzepatide: A Conceptual Framework | Authorea try { document.documentElement.classList.add('js'); } catch (e) { } var _gaq = _gaq || []; _gaq.push(['_setAccount', 'G-8VDV14Y67G']); _gaq.push(['_trackPageview']); (function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })(); Skip to main content Preprints Collections Wiley Open Research IET Open Research Ecological Society of Japan All Collections About About Authorea FAQs Contact Us Quick Search anywhere Search for preprint articles, keywords, etc. Search Search ADVANCED SEARCH SCROLL This is a preprint and has not been peer reviewed. Data may be preliminary. 11 September 2025 V1 Latest version Share on Rationale for DPP-4 Inhibitors as Bridge or Dose-Sparing Therapy in Patients Using GLP-1 Receptor Agonists or Tirzepatide: A Conceptual Framework Author : M 0009-0004-8362-9249 [email protected] Authors Info & Affiliations https://doi.org/10.22541/au.175762014.42205498/v1 360 views 177 downloads Contents Abstract Supplementary Material Information & Authors Metrics & Citations View Options References Figures Tables Media Share Abstract Background : Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonist tirzepatide provide significant glycemic control and weight loss, along with other benefits such as cardiovascular (CV) advantages. Despite these advancements, widespread use is mainly limited by gastrointestinal side effects, cost, and frequent shortages. The oral antidiabetic class dipeptidyl peptidase-4 inhibitors (DPP-4i), though less effective, are well-tolerated and more affordable. Current guidelines recommend against combining GLP-1RAs with DPP-4i, citing redundancy and limited clinical benefit. Methods : A narrative synthesis of the pharmacology, physiology, and clinical data related to incretin receptor agonists and DPP-4i was conducted to critically assess whether and when their combination can be safely and effectively used. Results and discussion : The standard guidelines recommendations against combining a DPP-4i with a GLP-1RA or tirzepatide are based on limited evidence. However, analyzing agents' different pharmacodynamics suggests potential complementarity rather than complete redundancy: incretin receptor agonists provide continuous, supraphysiological receptor activation, while DPP-4i extend endogenous GLP-1 and GIP activity, maintaining meal-related pulsatility. Additionally, DPP-4 cleaves multiple peptides beyond incretins, raising the possibility of other effects. Thus, DPP-4i could offer supportive benefits to incretin receptor agonist therapy: bridging during treatment gaps, dose-sparing when higher doses aren't tolerated, stabilizing weight control in obesity without diabetes, and maintaining incretin tone in resource-limited settings. Conclusion : Physiological reasoning and real-world needs support re-evaluating the potential of using an incretin receptor agonist with a DPP-4i. Rigorous crossover studies, randomized trials, and pharmacoeconomic analyses are urgently needed to determine if the theoretical synergy leads to clinically meaningful outcomes. Supplementary Material File (rationale for dpp-4 inhibitors as bridge or dose-sparing therapy in patients using glp-1 receptor agonists or tirzepatide.pdf) Download 352.05 KB Information & Authors Information Version history V1 Version 1 11 September 2025 Copyright This work is licensed under a Non Exclusive No Reuse License. Keywords diabetes dpp-4i glp-1ra mace obesity tirzepatide Authors Affiliations M 0009-0004-8362-9249 [email protected] Institute of Endocrinology and Metabolic Sciences, IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele View all articles by this author Metrics & Citations Metrics Article Usage 360 views 177 downloads .FvxKWukQNSOunydq8rnd { width: 100px; } Citations Download citation M. Rationale for DPP-4 Inhibitors as Bridge or Dose-Sparing Therapy in Patients Using GLP-1 Receptor Agonists or Tirzepatide: A Conceptual Framework. Authorea . 11 September 2025. DOI: https://doi.org/10.22541/au.175762014.42205498/v1 If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download. For more information or tips please see 'Downloading to a citation manager' in the Help menu . Format Please select one from the list RIS (ProCite, Reference Manager) EndNote BibTex Medlars RefWorks Direct import Tips for downloading citations document.getElementById('citMgrHelpLink').addEventListener('click', function() { popupHelp(this.href); return false; }); $(".js__slcInclude").on("change", function(e){ if ($(this).val() == 'refworks') $('#direct').prop("checked", false); $('#direct').prop("disabled", ($(this).val() == 'refworks')); }); View Options View options PDF View PDF Figures Tables Media Share Share Share article link Copy Link Copied! Copying failed. Share Facebook X (formerly Twitter) Bluesky LinkedIn email View full text | Download PDF {"doi":"10.22541/au.175762014.42205498/v1","type":"Article"} Now Reading: Share Figures Tables Close figure viewer Back to article Figure title goes here Change zoom level Go to figure location within the article Download figure Toggle share panel Toggle share panel Share Toggle information panel Toggle information panel Go to previous graphic Go to next graphic Go to previous table Go to next table All figures All tables View all material View all material xrefBack.goTo xrefBack.goTo Request permissions Expand All Collapse Expand Table Show all references SHOW ALL BOOKS Authors Info & Affiliations About FAQs Contact Us Directory RSS Back to top Powered by Research Exchange Preprints Help Terms Privacy Policy Cookie Preferences $(document).ready(() => setTimeout(() => { let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" ")); $.get("/resource/lodash?t="+_bnt); },4000)); (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'9fed714d594de2c5',t:'MTc3OTMwMjE0MQ=='};var a=document.createElement('script');a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();